Michael Russell Charlton
Physician in Rochester, MN
License number
Utah 8705293-1205
Issued Date
Jul 25, 2013
Expiration Date
Jan 31, 2018
Category
Physician
Type
Physician & Surgeon
Address
Address
Rochester, MN
Education
UNIVERSITY OF LONDON CHARING CROSS & WESTMINSTER
Professional information
See more information about Michael Russell Charlton at trustoria.com
Michael R Charlton, Rochester MN
Michael R Charlton, Rochester MN
Specialties:
Gastroenterologist
Address:
200 1St St Sw, Rochester, MN 55905
Education:
St. George's Hospital Medical School - Doctor of Medicine
Fletcher Allen Health Care-Medical Center Campus - Fellowship - Gastroenterology (Internal Medicine)
Fletcher Allen Health Care-Medical Center Campus - Residency - Internal Medicine
Fletcher Allen Health Care-Medical Center Campus - Fellowship - Gastroenterology (Internal Medicine)
Fletcher Allen Health Care-Medical Center Campus - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Gastroenterology (Internal Medicine), American Board of Internal Medicine Sub-certificate in Transplant Hepatology (Internal Medicine)
Animal Model For Hepatitis C Virus Infection
Animal Model For Hepatitis C Virus Infection
US Patent:
2009013, May 28, 2009
Filed:
Sep 29, 2005
Appl. No.:
11/576231
Inventors:
Michael R. Charlton - Rochester MN, US
Jeffrey L. Platt - Ann Arbor MI, US
Jeffrey L. Platt - Ann Arbor MI, US
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN
International Classification:
A01K 67/027
US Classification:
800 9, 800 18
Abstract:
The current document relates to transgenic rodents that have a nucleic acid molecule encoding a hepatocyte mitogen polypeptide.
Serum Biomarkers For Early Detection Of Acute Cellular Rejection
Serum Biomarkers For Early Detection Of Acute Cellular Rejection
US Patent:
8003333, Aug 23, 2011
Filed:
Sep 22, 2008
Appl. No.:
12/235292
Inventors:
Michael R. Charlton - Rochester MN, US
Assignee:
MAYO Foundation for Medical Education and Research - Rochester MN
International Classification:
G01N 33/53, G01N 33/49
US Classification:
435 71, 435 792, 435 793, 435 794, 435 795, 435366, 435372
Abstract:
The present invention provides an improved method of diagnosing a subject having received an organ transplant with Acute Cellular Rejection (ACR). The method comprises obtaining a biological sample from the subject, detecting an amount of at least one protein indicative of ACR in the sample, and comparing the amount of the protein in the sample to a control, wherein a difference between the amount of the protein in the sample relative to the control indicates the subject has or is developing ACR. The difference can be an increase or a decrease. In one version the biological sample comprises a serum sample, and the transplanted organ is selected from a heart, kidney, liver, bone marrow, pancreas, eye, lung or skin. A kit and methods of treating a subject having an organ transplant for ACR and treating an immune suppressed subject are also provided.
Methods And Materials For Reducing Liver Fibrosis
Methods And Materials For Reducing Liver Fibrosis
US Patent:
2013020, Aug 8, 2013
Filed:
Apr 22, 2011
Appl. No.:
13/643042
Inventors:
Michael R. Charlton - Rochester MN, US
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN
International Classification:
A61K 39/395, C12Q 1/68, G01N 33/566, A61K 31/7088, A61P 1/16
US Classification:
4241721, 514 44 A, 435 792, 435 613
Abstract:
This document relates to methods and materials for treating diseases or disorders that are caused by or associated with lumican deposition (e.g., liver fibrosis). For example, methods and materials for reducing liver fibrosis by reducing lumican expression or activity within a mammal (e.g., a human) are provided.
Assessing Non-Alcoholic Fatty Liver Disease
Assessing Non-Alcoholic Fatty Liver Disease
US Patent:
2012030, Nov 29, 2012
Filed:
Aug 13, 2012
Appl. No.:
13/584535
Inventors:
Michael R. Charlton - Rochester MN, US
International Classification:
G01N 33/53
US Classification:
435 79, 436501
Abstract:
The document provides methods and materials related to assessing NAFLD in a mammal. For example, methods and materials for determining whether or not a mammal has an NAFLD are provided. In addition, methods and materials for determining whether a mammal with an NAFLD has a severe or mild form of the NAFLD as well as methods and materials for determining whether a mammal with an NAFLD is likely to experience a severe or mild form of the NAFLD are provided.
Serum Biomarkers For Early Detection Of Acute Cellular Rejection
Serum Biomarkers For Early Detection Of Acute Cellular Rejection
US Patent:
2012001, Jan 19, 2012
Filed:
Jul 18, 2011
Appl. No.:
13/185306
Inventors:
Michael R. Charlton - Rochester MN, US
International Classification:
G01N 33/566, A61K 38/13, A61K 39/395, A61K 31/52, A61K 31/365, A61K 31/573, C12Q 1/48, A61K 31/436
US Classification:
4241331, 435 15, 435 792, 436501, 514 205, 514291, 5142632, 514470, 514179, 4241581
Abstract:
The present invention provides an improved method of diagnosing a subject having received an organ transplant with Acute Cellular Rejection (ACR). The method comprises obtaining a biological sample from the subject, detecting an amount of at least one protein indicative of ACR in the sample, and comparing the amount of the protein in the sample to a control, wherein a difference between the amount of the protein in the sample relative to the control indicates the subject has or is developing ACR. The difference can be an increase or a decrease. In one version the biological sample comprises a serum sample, and the transplanted organ is selected from a heart, kidney, liver, bone marrow, pancreas, eye, lung or skin. Methods of treating a subject having an organ transplant for ACR are also provided.
Assessing Non-Alcoholic Fatty Liver Disease
Assessing Non-Alcoholic Fatty Liver Disease
US Patent:
2009022, Sep 3, 2009
Filed:
Mar 1, 2007
Appl. No.:
12/280502
Inventors:
Michael R. Charlton - Rochester MN, US
International Classification:
G01N 33/53
US Classification:
435 71
Abstract:
The document provides methods and materials related to assessing NAFLD in a mammal. For example, methods and materials for determining whether or not a mammal has an NAFLD are provided. In addition, methods and materials for determining whether a mammal with an NAFLD has a severe or mild form of the NAFLD as well as methods and materials for determining whether a mammal with an NAFLD is likely to experience a severe or mild form of the NAFLD are provided.
Reducing Tumor Growth
Reducing Tumor Growth
US Patent:
2008023, Sep 25, 2008
Filed:
Jan 17, 2008
Appl. No.:
12/016062
Inventors:
Lewis R. Roberts - Rochester MN, US
Michael R. Charlton - Rochester MN, US
Michael R. Charlton - Rochester MN, US
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN
International Classification:
A61K 39/395, A61K 31/70, A61P 43/00
US Classification:
4241331, 4241301, 4241411, 514 44
Abstract:
This document provides methods and materials for reducing tumor growth in a mammal. For example, methods and materials for using PLVAP inhibitors to reduce tumor growth in a mammal (e.g., a human) are provided.